Dr. Glenn Gormley is Senior Executive Officer and the Global Head of Research & Development at Daiichi Sankyo Co., Ltd. He also holds the position of Chairman of the Board and President of Daiichi Sankyo Inc. in the United States. As head of global R&D, Dr. Gormley chairs the Executive Management decision body for R&D and oversees the R&D organization in the four regions: Americas, Europe, Japan and Asia. In his role as Chairman and President of Daiichi Sankyo, Inc., Dr. Gormley oversees the commercial and development organizations in the US.
He was formerly Chief Executive Officer of Gemin X Pharmaceuticals, a North American oncology company. Prior to Gemin X, Dr. Gormley held the position of Global Head of Clinical Development and Medical Affairs at Novartis. Before joining Novartis, Dr. Gormley served as Chief Medical Officer for AstraZeneca, where he continued his academic appointment as a member of the Clinical Faculty at New York University and served as a Trustee of the University of Delaware. Early in his career, Dr. Gormley held the position of VP of US Clinical Development at Merck.
Dr. Gormley volunteers on a number of boards and committees including the PhRMA Board of Directors, the PhRMA FDA and Biomedical Committee, the PhRMA Biomedical Advisory Counsel and the Board of Directors of the Biotechnology Industry Organization (BIO). He is a member of the University of Delaware College of Health Sciences oversight committee.
Dr. Gormley received his M.D. and Ph.D. in Chemistry from the University of Chicago and received board certifications in Pediatrics from UCLA and Endocrinology from New York University. He completed his post doc fellowship in oncology from the Ben May Institute in Chicago and has been the recipient of several Mac Arthur fellowships. He has remained committed to the fields of clinical pharmacology and endocrinology and published many papers of original research.